BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

5:22 PM
 | 
Jun 17, 2010
 |  BC Extra  |  Company News

FDA approves Tasigna for first-line Ph+ CML

FDA granted accelerated approval to Tasigna nilotinib from Novartis AG (NYSE:NVS; SIX:NOVN) for first-line treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in chronic...

Read the full 111 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >